BICO is conducting coverage surveys in eight Onchocerciasis-endemic districts: Blantyre, Mwanza, Mulanje, Phalombe, Chikwawa, Chiradzulu, Ntcheu, and Zomba, following Mass Drug Administration (MDA) conducted between October and December 2024. Initially, the program extended to Thyolo and Neno districts but has since stopped after recent study found that the presence of Onchocerciasis in these districts has dwindled. This activity is implemented by BICO to compare the results as presented by the MoH to what is actually on the ground. The Survey will seek to address the Ivermectin geographical and therapeutic coverages and their associated reasons including the MDA method used, protocol adherence and side effects recorded.
